Steven Gannon - 11 Aug 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Director
Issuer ticker: XENE
Reported as of: 11 Aug 2026
Net transaction value: -$640,550
SEC form: 4
Accepted by SEC: 13 Aug 2026, 16:33:27 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nathaniel Adams, Attorney-in-fact

Key filing fact

Steven Gannon filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 13 Aug 2026.

Key facts

This page summarizes Steven Gannon's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2026, 16:33.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$640,550.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643085 Primary reporting owner

GANNON STEVEN

Relationship: Director
Address: 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENE transaction

Common Shares

Sale

Transaction value: $640,550
Shares: -10,000
Change %: -84%
Price: $64.06
Shares after: 1,870
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $64.0517 to $64.078, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.